Belgian biotechnology company Agomab Therapeutics NV (Agomab) has acquired Origo Biopharma, which is developing an innovative platform for TGF-beta-inhibiting locally acting drugs for the treatment of fibrosis in various tissues and cancer.

This biotechnology company based in Touro (Galicia) and Barcelona is funded by Asabys Partners, members of CataloniaBio &  HealthTech, and the Xunta de Galicia. Asabys Partners led a Seed round in June 2020, and since then have worked with the founders and management team to capture talent, expand the project portfolio, and develop the most advanced product to clinical stages.

The operation  with the Belgian biotechnology company is the first divestment of Asabys  Partners, a venture capital manager founded by Josep Ll. Sanfeliu and Clara Campàs and owned by Alantra, through its fund Sabadell Asabys Health  Innovation Investments, SCR, SA. The fund was launched in 2019 with 87  million euros to invest (Banc Sabadell as a reference investor) and currently has 12 companies in its portfolio. Asabys Partners value it as a sign of success in its approach to investing in good science projects, creating robust teams, and developing solid assets to cover unmet medical needs, in therapeutic areas where there are corporate movements.